Redhill Biopharma Ltd (RDHL NASDAQ) stock market data APIs
$5.6
0.09(1.6%)
as of January 14, 2025
Redhill Biopharma Ltd Financial Data Overview
Price chart is built with
Anychart
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Prev. Close
5.506
Open
5.6
Volume
10 011
High
5.73
Low
5.41
52 wk Range
5.41-31.5025
Market Cap
7 051 K
Shares Outstanding
1 281 K
Revenue
3 707 K
EPS
-200
Beta
3.671
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Redhill Biopharma Ltd data using free add-ons & libraries
Get Redhill Biopharma Ltd Fundamental Data
Redhill Biopharma Ltd Fundamental data includes:
- Net Revenue: 3 707 K
- EBITDA: -20 941 000
- Earnings Per Share: -302
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-08-29
- EPS/Forecast: -30
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Redhill Biopharma Ltd News
New
Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar?
Biotechnology company Gilead Sciences (NASDAQ:GILD) wasn’t a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024. Gil...
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viabil...
Morning Brew: Bank of America Predicts S&P 500 Upside, Kraft Heinz Approves $3B Buyback
Bank of America's global research team has outlined 10 key investment themes for 2024, forecasting a 10% rise in the S&P 500 (SP500), alongside potential interest rate cuts and Brent oil averaging $90...
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
RedHill's partner, Gaelan Medical, part of the Ghassan Aboud Group (GAG), receives marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia Gaelen placed a meaningful ini...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
